TB-500 is a synthetic peptide fragment of Thymosin Beta-4 (TB4), a naturally occurring 43-amino acid protein found in virtually all human and animal cells. TB-500 specifically replicates the active region (amino acids 17-23) of Thymosin Beta-4 responsible for actin binding and cell migration. Thymosin Beta-4 plays a critical role in tissue repair, wound healing, and anti-inflammatory processes throughout the body. TB-500 is widely used for injury recovery, particularly for slow-healing injuries like tendon damage, ligament sprains, and muscle tears. It has also gained popularity in veterinary medicine, especially equine sports medicine.
Notes
TB-500 is a research peptide, not FDA-approved for human use. Thymosin Beta-4 (the parent protein) has been studied in clinical trials for corneal wound healing and cardiac repair. TB-500 is widely used in veterinary medicine (horses, dogs) for injury recovery.
TB-500 works primarily through its interaction with actin, a key structural protein in all cells. By sequestering G-actin monomers, TB-500 promotes cell migration, which is essential for wound healing, as cells must migrate to the injury site to initiate repair. It upregulates actin polymerization, allowing cells to move through damaged tissue. TB-500 also promotes angiogenesis (new blood vessel formation), reduces inflammation by downregulating inflammatory cytokines, and stimulates keratinocyte and endothelial cell migration. It has demonstrated the ability to promote hair follicle growth and cardiac tissue repair in animal models.
TB-500 is a small, water-soluble peptide that distributes systemically after subcutaneous injection. Its relatively long effective duration (7-10 days) is due to the stability of Thymosin Beta-4 fragments and their incorporation into cellular repair processes rather than simple plasma half-life. The peptide travels through the bloodstream to sites of injury and inflammation. It is metabolized through normal proteolytic processes and cleared renally.
Typical Dose
Loading phase: 5-10 mg per week for 4-6 weeks (typically split into 2-3 injections per week). Maintenance phase: 2.5-5 mg every 2 weeks, or 2.5 mg weekly. Some protocols use a single 5 mg injection once weekly during loading.
Frequency
Loading: 2-3 times per week (e.g., 2.5 mg Monday and Thursday). Maintenance: once weekly or every two weeks.
Administration
Subcutaneous or intramuscular injection. Unlike BPC-157, TB-500 is systemically active regardless of injection site, so there is no need to inject near the injury. Subcutaneous injection in the abdominal area is most common.
Half-Life
Estimated 7-10 days (based on the pharmacokinetics of Thymosin Beta-4)
Contraindications
No PCT required. TB-500 has zero effect on the hormonal system, HPTA, or sex hormone production. It can be used alongside hormonal compounds or SARMs without interaction.